New IAVI white paper identifies critical gaps across R&D, equitable access, and financing.
This EGM characterizes the evidence base of SBCC interventions for strengthening HIV prevention and research among AGYW in LMICs.
Janssen-sponsored trial discontinued due to lack of efficacy.
Reflecting on the Ebola Sudan outbreak in Uganda, Swati Gupta suggests a global solution to prepare for emerging infectious disease outbreaks.
Blog perspective from a graduate of the first cohort of the IAVI ADVANCE Leadership Development Program.
First shipment of IAVI’s Sudan virus (SUDV) vaccine candidate has arrived in Entebbe, Uganda.
Sustaining momentum in research, development, and innovation for HIV prevention and other disease areas in the context of shrinking global resources. ...
In the wake of cutting-edge science, it is essential to nurture a community-rooted and participant-centered approach to accelerate vaccine research.
Jama Dalel, Ph.D., post-doctoral researcher, IAVI–Human Immunology Laboratory (HIL), Imperial College, London
Jyoti Sutar, Ph.D., senior research associate, Antibody Translational Research Program (previously the HIV Vaccine Translational Research Laboratory) ...
We must plan for their introduction and demand what is needed for new TB vaccines to reach End TB targets, experts say.